Bio-Rad's RAPID'E.coli 2 Agar for Water Testing Receives EPA Approval to detect E. coli and Total Coliforms in Drinking Water

Date: 
06/23/2021
RAPID'<em>E.coli™</em> 2 Agar offers direct and simultaneous identification of Escherichia coli and total coliforms in drinking and untreated water

RAPID'E.coli™ 2 Agar offers direct and simultaneous identification of Escherichia coli and total coliforms in drinking water.

HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that its RAPID'E.coli™ 2 Agar for water testing has received approval from the U.S. Environmental Protection Agency (EPA) for testing drinking water for Escherichia coli (E. coli) and total coliforms. The solution includes chromogenic medium and a selective supplement that can detect these bacteria without the need for a confirmation step.

The Bio-Rad RAPID'E.coli™ 2 Agar for water testing provides simultaneous enumeration of E. coli and other coliforms, delivering results in less than 24 hours. The bright color utilized in the medium offers strong contrast in helping to identify the presence of target organisms from interfering flora.

Standard methods to test water for E. coli and coliforms usually involves a series of complex steps, and the results often lack selectivity, which can be challenging for water testing since interfering flora may be abundant, particularly in nontreated water sources such as spring water and wells. The RAPID'E.coli™ 2 Agar for water testing offers direct and specific discrimination of E. coli from other coliforms.

"Our RAPID'E.coli™ 2 Agar for water testing reflects Bio-Rad's commitment to providing innovative solutions for water safety testing," said Jean-Francois Chauvet, Vice President and General Manager, Bio-Rad Applied Markets. "The stringent and comprehensive requirements required for EPA validation are well aligned with our goal to provide high-quality products for water testing as well as our goal to streamline workflows and improve efficiencies."

The EPA approval provides validation for use RAPID'E.coli™ 2 Agar for water testing in U.S. laboratories. The method has also received the NF Validation Certificate, a certification from the AFNOR Groupe designed to validate commercial microbial analysis kits that is recognized in Europe, the Middle East, and Asia.

Please visit bio-rad.com/water to learn more about Bio-Rad's solutions for water testing.

BIO-RAD, and RAPID'E.coli are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. Please visit bio-rad.com for further information.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contacts:
Bio-Rad Laboratories, Inc.
Wendy Lauer
520-741-5653
wendy_lauer@bio-rad.com

CG Life
Ben Marcus
847-302-8430
bmarcus@cglife.com